Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) is now available.
Pharmaron Beijing Co., Ltd. announced the results of its Annual General Meeting for 2024 and the first A and H share class meetings for 2025, held on June 20, 2025. The meetings were conducted in compliance with PRC Company Law, and all resolutions were passed by poll. The company also introduced a profit distribution plan for 2024, appointed a new non-executive director, and made amendments to its Articles of Association. These developments are expected to impact the company’s governance and shareholder engagement positively.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is involved in providing a range of services and products related to drug development and manufacturing, focusing on both A shares and H shares in the market.
Average Trading Volume: 9,275,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.55B
For a thorough assessment of 3759 stock, go to TipRanks’ Stock Analysis page.